HomeQuestion

Assuming a clinical trial is unavailable, would you consider tazemetostat in a patient with metastatic INI1/SMARCB1 deficient sinonasal carcinoma?

1 Answers

Mednet Member

Medical Oncology · University of Virginia

I would certainly consider Tazmetostat for INI deficient SNUC, if progressed on front-line therapy and no trials available.